Cretostimogene grenadenorepvec clinical trials
Also written CG0070.
How each study uses cretostimogene grenadenorepvec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cretostimogene grenadenorepvec studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2020 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 2
CG Oncology, Inc. (6) · H. Lee Moffitt Cancer Center and Research Institute (2) · Lepu Biopharma Co., Ltd. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test cretostimogene grenadenorepvec, phase 3 first.
- Nov 2026A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTPhase 3 · CG Oncology, Inc.
- Mar 2027Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCPhase 2 · CG Oncology, Inc.
- Sep 2027Study of CG0070 After Transurethral Resection in Patients With IR NMIBCPhase 1 · H. Lee Moffitt Cancer Center and Research Institute
Studies
Open first, then newest update. How each study uses cretostimogene grenadenorepvec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCRecruitingPhase 2CG Oncology, Inc.NCT06567743Written as Cretostimogene Grenadenorepvec
- Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinRecruitingPhase 2Lepu Biopharma Co., Ltd.NCT07283835Written as Cretostimogene Grenadenorepvec
- Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinActive, not recruitingPhase 3CG Oncology, Inc.NCT04452591Written as Cretostimogene Grenadenorepvec
- Study of CG0070 After Transurethral Resection in Patients With IR NMIBCActive, not recruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06253845Written as CG0070
- A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTActive, not recruitingPhase 3CG Oncology, Inc.NCT06111235Written as Cretostimogene Grenadenorepvec
- Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder CancerWithdrawnPhase 2CG Oncology, Inc.NCT02143804Written as oncolytic adenovirus expressing GMCSF
- Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBCCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT04610671Written as CG0070
- Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinCompletedPhase 2CG Oncology, Inc.NCT04387461Written as CG0070
- Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG FailureCompletedPhase 2CG Oncology, Inc.NCT02365818Written as CG0070
Codes
What other systems call cretostimogene grenadenorepvec · ClinicalTrials.gg INT018024
- UNII (FDA) THP9ML4NTZCRETOSTIMOGENE GRENADENOREPVECOne source FDA
- NCI Thesaurus C48412Cretostimogene GrenadenorepvecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | THP9ML4NTZ | CRETOSTIMOGENE GRENADENOREPVEC | One source FDA |
| NCI Thesaurus | C48412 | Cretostimogene Grenadenorepvec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.